Drugs in MeSH Category Nitric Oxide Donors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ISORDIL	isosorbide dinitrate	TABLET;ORAL	012093-001	Jul 29, 1988	AB	RX	Yes	Yes
Hikma Intl Pharms	ISOSORBIDE DINITRATE	isosorbide dinitrate	TABLET;ORAL	088088-002	Oct 29, 1987	AB	RX	No	No
Zydus Lifesciences	ISOSORBIDE DINITRATE	isosorbide dinitrate	TABLET;ORAL	213057-005	Nov 20, 2019	AB	RX	No	No

Last updated: July 25, 2026

Market Dynamics and Patent Landscape for Nitric Oxide Donors (NLM MeSH Class)

Nitric oxide (NO) donor therapeutics sit across cardiovascular and pulmonary indications, with patent estates concentrated in specific active ingredients (notably organic nitrates, nitrite salts, and inhaled NO products) plus formulation and method-of-use extensions. Most real market exclusivity is driven by (1) the ongoing Orange Book status of branded products and (2) device- and delivery-system constraints in inhaled NO and aerosolized nitrite/nitrate systems. Patent litigation and Paragraph IV risks are most visible where oral or topical nitrate products have well-developed generic entry routes; inhaled NO has structurally higher barriers due to delivery and manufacturing validation requirements.

Which drugs are Nitric Oxide donors in MeSH class, and how are they marketed?

MeSH “Nitric Oxide Donors” spans multiple drug classes, but market participation is dominated by a few commercially durable categories: organic nitrates (antianginal/anti-ischemic), inhaled nitric oxide (pulmonary hypertension and neonatal indications), and NO-donor prodrugs or nitrite/nitrate systems used for cardiovascular or pulmonary targets. Commercial brands typically cluster into three buckets based on delivery route and payer acceptance.

Top NO-donor categories by route

• Oral and sublingual organic nitrates
  • Active ingredients in practice: nitroglycerin formulations and related nitrate esters.
  • Market role: long-standing angina management, with recurrent branded-to-generic transitions driven by expiring primary patents and renewals.
• Transdermal nitrates
  • Active ingredients in practice: nitroglycerin patches and related systems.
  • Market role: adherence and sustained release. Formulation and membrane/adhesive patents often extend lifecycle even when API patents expire.
• Inhaled nitric oxide (gas)
  • Active ingredient: nitric oxide (NO), typically delivered via an integrated device system.
  • Market role: acute pulmonary indication management; high device specificity raises manufacturing and IP barriers.
• Other nitrite/nitrate delivery approaches
  • Includes systems intended to generate NO in vivo. Market presence is smaller and more patent-intensive, with less generic competition because delivery chemistry and bioactivation can be proprietary.

Commercial dynamics

• Oral/transdermal nitrates: generics dominate in many jurisdictions where primary API and basic formulation patents have expired. Remaining branded differentiation is mostly formulation bioavailability, tolerability, and adherence.
• Inhaled NO: branded incumbents retain pricing power longer due to integrated delivery systems, training requirements, and tightly controlled manufacturing specifications that act as de facto barriers.

What patents protect nitric oxide donor drugs, and how many patent families matter?

Patent protection for NO donor therapeutics is typically layered: composition-of-matter, polymorph/crystal form, process, formulation, and method-of-use. The patent estate size varies more by delivery system than by NO chemistry alone.

Patent estate components you should expect

1. Composition-of-matter
   • Often relevant for novel NO-donor prodrugs or nitrite/nitrate chemistry.
   • Less common as a long-lived barrier for classic nitrates when API patents have already lapsed.
2. Formulation and dosage form
   • Oral: controlled-release coatings, matrix systems, and bioavailability improvements.
   • Transdermal: adhesive systems, rate-controlling membranes, and backing layers.
   • Inhaled systems: device integration and stabilization approaches.
3. Manufacturing and process
   • Particularly important where formulation stability and NO release kinetics are sensitive.
4. Method-of-use
   • Pulmonary hypertension subpopulations, timing of administration, and combination regimens.
   • Neonatal use cases are often supported by clinical and regulatory-linked method patents.

How to count “families” vs “assertable patents”

• For litigation and licensing, focus on patents with remaining legal life and clear claim coverage over:
  • The approved indication(s),
  • The specific dosage form,
  • The manufacturing method or stability characteristics if generic copies are constrained by process.
• For portfolio planning, count both:
  • Active families with at least one unexpired member in the US/EP,
  • Regulatory-linked families that appear in Orange Book (US) or national registers (EU).

Which nitric oxide donor brands are in the US Orange Book, and what is their exclusivity status?

US exclusivity for NO donors often reflects two realities:

• Long-standing nitrate products frequently show no remaining patent barrier beyond potentially formulation/device-specific patents.
• Inhaled NO products and certain nitrate formulations can still show listed patents, including those tied to dosage form or method of use.

Orange Book pattern by NO-donor type

• Oral/transdermal: Orange Book listings can persist due to formulation patents even when core API patents are expired.
• Inhaled NO gas: Orange Book listings, when present, typically track delivery system and method claims.
• Non-classic NO donor prodrugs: more likely to have multi-parameter patent estates with stronger generic delay potential.

Featured-snippet answer

Orange Book status for NO donor drugs is usually short on remaining exclusivity for classic nitrates, but longer for branded delivery systems and method-of-use claims, especially where device integration and stability requirements constrain generic replication.

(Note: Producing an Orange Book table with specific drug names and listed patents requires drug-level query scope and verified Orange Book listings. Without that, this section cannot be completed accurately.)

When do nitric oxide donor patents expire, and what timeline drives generic entry risk?

Generic risk timing for NO donor drugs depends on the earliest of:

• earliest composition/formulation patent expiry,
• any pediatric exclusivity extension,
• any market exclusivity blocks tied to new indication or NDA supplements.

Typical lifecycle timeline structure

• Primary API (composition) tends to expire first for classic nitrates.
• Formulation/delivery patents can extend US exclusivity by years, shifting Orange Book hurdles from API to dosage-form copy.
• Method-of-use patents keep risk elevated when approved indications map to claim scope, even after API expiry.

Risk windows by drug category

• Classic oral nitrates: generic entry risk typically high immediately after the last relevant listed formulation patent expires.
• Transdermal systems: entry risk pushed later when rate-controlling and adhesive patents remain.
• Inhaled NO gas: entry risk is lower in practice because even where patents expire, manufacturing and delivery system replication can face practical and IP constraints.

How strong is the patent estate for nitric oxide donors, and what claim types drive enforceability?

Patent strength for NO donors is usually determined by:

• claim language specificity around dosage form or release kinetics,
• whether patents are actually listed to FDA-approved strengths,
• enforceability history (whether claims have been survived, allowed, or sustained in litigation).

High-enforceability claim types

• Formulation claims tied to measurable release characteristics (rate-controlling layers, stabilization).
• Method-of-use claims with narrow, clinically anchored parameters that map to an FDA-labeled regimen.
• Manufacturing-process claims if generic applicants can’t credibly use “equivalent” processes without changing critical quality attributes.

Lower-enforceability claim types

• Broad genus composition claims that are easier to design around.
• Process claims where generic manufacturing can switch to an unclaimed process with equivalent performance.
• Claims not linked to approved strengths/indications via Orange Book listing.

Which companies are likely challenging or defending nitric oxide donor patents?

In the US, generic challenges cluster around branded NO donor products with:

• Orange Book-listed formulation or method-of-use patents,
• predictable manufacturing routes,
• credible Paragraph IV filings.

What to look for in market intelligence

• Repeat filers across nitrate/transdermal categories.
• Generic applicants that specialize in controlled-release and transdermal technology.
• Defendants that hold delivery-system or formulation patents tied to controlled release or stability.

(A defensible list of companies and specific challenges requires verified Paragraph IV and litigation dockets per product, which cannot be produced from the provided prompt.)

What Paragraph IV litigation patterns affect nitric oxide donor drugs?

Across NO donor drug categories, Paragraph IV litigation typically turns on:

• whether generics can provide a Section viii carve-out (design around),
• whether claim scope covers the approved formulation and labeled strength,
• whether method-of-use claims are invalid over prior art or obviousness.

Common litigation themes

• Design-around of formulation: generic tries to show non-infringement by changing release matrix or adhesive system.
• Indefiniteness and enablement: especially for formulation release and stability parameters.
• Obviousness: prior art nitrates and known NO donor chemistry are repeatedly used in invalidity.

(Without product-level patent numbers and case citations, this section cannot be tied to actual docket outcomes.)

What generic entry risks exist for nitric oxide donor formulations?

Entry risks differ by dosage form.

Oral nitrates

• Generic entry risk tracks listed controlled-release/formulation patents more than API.
• Bioequivalence routes can be straightforward unless a formulation patent claims specific release behavior.

Transdermal nitrates

• Highest generic engineering complexity: adhesive composition, membrane thickness, and controlled release.
• Even when generics are bioequivalent, formulation patents can still block entry if claims cover structure and functional release.

Inhaled NO

• “Generic” entry is often not a simple substitution. Device and gas delivery integration are the critical barrier.
• Even where API is identical (NO), patents can still cover delivery system, stabilization, and use regimens.

How do inhaled nitric oxide products compare on patent and market dynamics?

Inhaled NO differs because the active ingredient is gas and the value is in:

• delivery accuracy,
• monitoring and safety controls,
• dosing regimen protocols.

Patent leverage drivers

• device integration,
• dosing controls,
• method-of-use for acute pulmonary settings and neonates.

Commercial implications

• High switching friction in hospitals.
• Procurement decisions reflect device ecosystem and training, extending practical exclusivity beyond formal patent life.

How do nitric oxide donor patents differ across geographic markets (US vs EU)?

For NO donors, geographic divergence comes from:

• differing patentability standards for formulation/process claims,
• enforcement intensity and litigation tempo,
• supplemental protection certificates (SPCs) in the EU when applicable.

US vs EU typical pattern

• US: Orange Book-driven incentives for Paragraph IV.
• EU: SPCs and national courts shape enforceability and timelines for formulation and method-of-use.

(A geography-specific mapping with exact expiry dates requires jurisdiction-specific patent lists.)

What formulations are protected by nitric oxide donor patents?

Formulation protection usually focuses on measurable attributes:

• controlled-release profiles,
• stabilization and shelf-life,
• transdermal delivery kinetics,
• inhalation delivery system integration.

Formulation clusters to expect

• Controlled-release tablets/capsules (release kinetics patents)
• Transdermal patches (adhesive and membrane patents)
• Oromucosal and sublingual systems (bioavailability and residence time)
• Inhaled delivery systems (dose control and safety monitoring protocols)

What regulatory status issues interact with nitric oxide donor IP (FDA pathways)?

Regulatory strategy affects IP risk:

• If a generic applicant uses ANDA, Paragraph IV is the main patent pathway.
• New formulations or new indications can shift listing strategy (NDA supplements).

Key intersection

• Orange Book listing after an NDA supplement extends enforcement even when the API is old.
• For NO donor delivery systems, changes in dosage form can trigger new patent listings.

(This section cannot be populated with pathway-by-product detail without product-specific regulatory data.)

Key Takeaways

• Patent protection for nitric oxide donors is layered, with enforceability most often driven by formulation and delivery system patents rather than classic API chemistry.
• Market exclusivity is shortest for older oral nitrates and longest where patents connect to dosing regimens and delivery systems (especially inhaled NO).
• Generic entry risk is highest when the last listed formulation/method patent expires and when claim scope directly matches the FDA-approved strength and route.
• Real switching barriers frequently come from hospital procurement and device ecosystem constraints, not only formal patent term.

FAQs

1. Which nitric oxide donor drugs have the most remaining US Orange Book patent listings?
2. Do inhaled nitric oxide products face biosimilar-style competition, or are they mostly protected by device and process IP?
3. What claim types most often survive invalidity challenges in nitric oxide donor formulation litigation?
4. How do transdermal nitroglycerin patch patents typically extend exclusivity relative to oral nitrate patents?
5. What factors increase the likelihood that a generic ANDA for a nitric oxide donor will file a successful Paragraph IV?

References

1. NLM. Medical Subject Headings (MeSH). “Nitric Oxide Donors.” National Library of Medicine.
2. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). FDA.